Disease-modifying activity of malononitrilamides, derivatives of leflunomide's active metabolite, on models of rheumatoid arthritis.
Schorlemmer
H U
HU
Research Laboratories, Hoechst Marion Roussel Deutschland GmbH, DG Rheumatology, Frankfurt, Germany. hansulrich.schorlemmer@hmrag.com
Kurrle
R
R
Schleyerbach
R
R
Bartlett
R R
RR
D000178:Acrylamides / Q000627:therapeutic use*; D000480:Alkynes; D000814:Aniline Compounds / Q000627:therapeutic use*; D000818:Animals; D001169:Arthritis, Experimental / Q000188:drug therapy*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D002208:Caproates / Q000627:therapeutic use*; D003437:Crotonates; D004305:Dose-Response Relationship, Drug; D006885:Hydroxybutyrates / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007555:Isoxazoles; D009570:Nitriles; D051381:Rats; D011917:Rats, Inbred Lew; D014052:Toluidines
D000178:Acrylamides; D000480:Alkynes; D000814:Aniline Compounds; D002208:Caproates; D003437:Crotonates; D006885:Hydroxybutyrates; D007166:Immunosuppressive Agents; D007555:Isoxazoles; D009570:Nitriles; D014052:Toluidines; C115284:2-cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)-2-hepten-6-ynamide; C527525:teriflunomide; C116406:HMR 1279